Harbour Capital Advisors LLC boosted its position in shares of Celgene Corporation (NASDAQ:CELG) by 0.7% during the first quarter, Holdings Channel reports. The fund owned 12,197 shares of the biopharmaceutical company’s stock after buying an additional 83 shares during the period. Harbour Capital Advisors LLC’s holdings in Celgene Corporation were worth $1,518,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in CELG. Charter Trust Co. increased its stake in shares of Celgene Corporation by 55.2% in the first quarter. Charter Trust Co. now owns 3,781 shares of the biopharmaceutical company’s stock worth $470,000 after buying an additional 1,345 shares during the last quarter. CHURCHILL MANAGEMENT Corp increased its stake in Celgene Corporation by 95.1% in the first quarter. CHURCHILL MANAGEMENT Corp now owns 41,196 shares of the biopharmaceutical company’s stock worth $5,126,000 after buying an additional 20,077 shares during the last quarter. Gibraltar Capital Management Inc. increased its stake in Celgene Corporation by 0.9% in the first quarter. Gibraltar Capital Management Inc. now owns 30,206 shares of the biopharmaceutical company’s stock worth $3,759,000 after buying an additional 271 shares during the last quarter. Hills Bank & Trust Co. increased its stake in Celgene Corporation by 2.1% in the first quarter. Hills Bank & Trust Co. now owns 10,763 shares of the biopharmaceutical company’s stock worth $1,340,000 after buying an additional 218 shares during the last quarter. Finally, Boltwood Capital Management increased its stake in Celgene Corporation by 13.9% in the first quarter. Boltwood Capital Management now owns 6,770 shares of the biopharmaceutical company’s stock worth $842,000 after buying an additional 825 shares during the last quarter. Hedge funds and other institutional investors own 78.41% of the company’s stock.

Shares of Celgene Corporation (CELG) traded up 0.18% during trading on Friday, hitting $130.61. 2,735,623 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $134.14 and its 200 day moving average is $124.30. The firm has a market capitalization of $102.18 billion, a PE ratio of 40.45 and a beta of 1.89. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $139.00.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. The company had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s revenue for the quarter was up 18.7% compared to the same quarter last year. During the same period last year, the firm earned $1.44 EPS. On average, equities research analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/13/celgene-corporation-nasdaqcelg-position-raised-by-harbour-capital-advisors-llc.html.

CELG has been the subject of a number of research reports. BTIG Research reiterated a “buy” rating and set a $138.00 price target on shares of Celgene Corporation in a research report on Wednesday, May 24th. Argus upgraded shares of Celgene Corporation from a “hold” rating to a “buy” rating and lifted their price target for the company from $96.93 to $160.00 in a research report on Monday, July 31st. Jefferies Group LLC reiterated a “buy” rating and set a $160.00 price target on shares of Celgene Corporation in a research report on Tuesday, July 11th. Zacks Investment Research downgraded shares of Celgene Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Finally, Cantor Fitzgerald set a $160.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 6th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $147.00.

In other news, Director Gilla Kaplan sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the completion of the transaction, the director now directly owns 76,301 shares of the company’s stock, valued at approximately $10,264,010.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the transaction, the insider now directly owns 4,004 shares of the company’s stock, valued at $481,200.72. The disclosure for this sale can be found here. Insiders have sold a total of 235,255 shares of company stock valued at $31,377,042 over the last ninety days. 0.95% of the stock is owned by insiders.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.